When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
Impact of disability status on ischemic stroke costs in Canada in the first year.
BACKGROUND Longitudinal , patient-level data on re source use and costs after an ischemic stroke are lacking in Canada . The objectives of this analysis were to calculate costs for the first year post-stroke and determine the impact of disability on costs . METHODOLOGY The Economic Burden of Ischemic Stroke ( BURST ) Study was a one-year prospect i ve study with a cohort of ischemic stroke patients recruited at 12 Canadian stroke centres . Clinical history , disability , health preference and re source utilization information was collected at discharge , three months , six months and one year . Re sources included  direct medical costs ( 2009 CAN$ ) such as emergency services , hospitalizations , rehabilitation , physician services , diagnostics , medications , allied health professional services , homecare , medical/assistive devices , changes to residence and paid caregivers , as well as indirect costs . Results were stratified by disability measured at discharge using the modified Rankin Score ( mRS ) : non-disabling stroke ( mRS 0 - 2 ) and disabling stroke ( mRS 3 - 5 ) . RESULTS We enrolled 232 ischemic stroke patients ( age 69.4 ± 15.4 years ; 51.3 % male ) and 113 ( 48.7 % ) were disabled at hospital discharge .  The average annual cost was $ 74,353 ; $ 107,883 for disabling strokes and $ 48,339 for non-disabling strokes . CONCLUSIONS An average annual cost for ischemic stroke was calculated in which a disabling stroke was associated with a two-fold increase in costs compared to NDS . Costs during the hospitalization to three months phase were the highest contributor to the annual cost . A " back of the envelope " calculation using 38,000 stroke admissions and the average annual cost yields $ 2.8 billion as the burden of ischemic stroke
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .